Early adolescent cannabis exposure and positive and negative dimensions of psychosis

Addiction
N C StefanisJ van Os

Abstract

To investigate the effect of exposure to cannabis early in adolescence on subclinical positive and negative symptoms of psychosis. Cross-sectional survey in the context of an ongoing cohort study. Government-supported general population cohort study. A total of 3500 representative 19-year olds in Greece. Subjects filled in the 40-item Community Assessment of Psychic Experiences, measuring subclinical positive (paranoia, hallucinations, grandiosity, first-rank symptoms) and negative psychosis dimensions and depression. Drug use was also reported on. Use of cannabis was associated positively with both positive and negative dimensions of psychosis, independent of each other, and of depression. An association between cannabis and depression disappeared after adjustment for the negative psychosis dimensions. First use of cannabis below age 16 years was associated with a much stronger effect than first use after age 15 years, independent of life-time frequency of use. The association between cannabis and psychosis was not influenced by the distress associated with the experiences, indicating that self-medication may be an unlikely explanation for the entire association between cannabis and psychosis. These results add credence to the...Continue Reading

References

Apr 1, 1987·Paediatric and Perinatal Epidemiology·C Tzoumaka-Bakoula
Apr 1, 1994·Archives of General Psychiatry·D H LinszenM E Lenior
Jun 1, 1993·The British Journal of Psychiatry : the Journal of Mental Science·D A KibelP F Liddle
Jun 1, 1996·Addiction·J H WilliamsJ N Rawlins
Jan 1, 1997·Progress in Neuro-psychopharmacology & Biological Psychiatry·B Y Glenthøj, R Hemmingsen
Mar 4, 1998·Psychological Medicine·H VerdouxM L Bourgeois
Sep 9, 2000·Schizophrenia Research·J van OsA Ravelli
Dec 29, 2000·The Journal of School Health·M A Pérez, H Pinzon-Pérez
Mar 30, 2001·Schizophrenia Research·P D SkosnikS Park
Nov 13, 2001·Clinical Psychology Review·L C Johns, J van Os
Jan 5, 2002·The Journal of Nervous and Mental Disease·J A NunnE R Peters
Feb 19, 2002·Psychiatry Research·Patrick DumasThierry d'Amato
Apr 10, 2002·Acta Psychiatrica Scandinavica·L A Núñez, M Gurpegui
May 11, 2002·Current Psychiatry Reports·Hiroshi Ujike
Aug 16, 2002·American Journal of Epidemiology·J van OsH Verdoux
Sep 21, 2002·Social Psychiatry and Psychiatric Epidemiology·Jim van OsWilma Vollebergh
Nov 5, 2002·Schizophrenia Research·Hélène VerdouxJim van Os
Nov 26, 2002·BMJ : British Medical Journal·George C PattonWayne Hall
Nov 26, 2002·BMJ : British Medical Journal·Louise ArseneaultTerrie E Moffitt
Jan 23, 2003·Psychological Medicine·D M FergussonN R Swain-Campbell
Mar 5, 2003·Social Psychiatry and Psychiatric Epidemiology·M HanssenJ van Os
Jun 25, 2003·Drug and Alcohol Dependence·Louisa DegenhardtMichael Lynskey

❮ Previous
Next ❯

Citations

May 24, 2007·Social Psychiatry and Psychiatric Epidemiology·Aikaterini KapiChryssa Bakoula
Jul 1, 2008·Social Psychiatry and Psychiatric Epidemiology·Ippolyti VassiChryssa Bakoula
Mar 24, 2009·Social Psychiatry and Psychiatric Epidemiology·E DaneluzzoA Rossi
Jul 25, 2009·Psychopharmacology·Emilio Fernandez-EspejoFernando Rodriguez de Fonseca
Jul 18, 2009·European Archives of Psychiatry and Clinical Neuroscience·Deepak Cyril D'SouzaMohini Ranganathan
Jul 3, 2013·Asian Journal of Psychiatry·Preeti Parakh, Debasish Basu
May 20, 2008·Psychological Medicine·W VelingH W Hoek
Oct 12, 2010·Psychological Medicine·C D SchubartM P M Boks
Jul 16, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Colm M P O'TuathaighJohn L Waddington
Mar 22, 2012·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Aine T BehanDavid R Cotter
Aug 30, 2008·Schizophrenia Bulletin·Cécile HenquetRobin M Murray
Apr 24, 2009·Schizophrenia Bulletin·Johanna KoskinenJouko Miettunen
Jan 15, 2013·Schizophrenia Bulletin·Nikos C StefanisVera Anne Morgan
Apr 28, 2006·Current Opinion in Psychiatry·Jim van OsPhilippe Delespaul
Apr 28, 2006·Current Opinion in Psychiatry·Ilana Crome, Roger Bloor
Mar 29, 2011·Molecular Interventions·Kathryn A SeelyJeffery H Moran
Jul 25, 2006·Archives of Disease in Childhood·P A McArdle
May 17, 2006·Reviews on Environmental Health·H D MaharajhN S Baboolal
Apr 12, 2013·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Shivakumar SubbannaBalapal S Basavarajappa
Jan 30, 2014·Annual Review of Clinical Psychology·Ruud van Winkel, Rebecca Kuepper
Dec 17, 2008·Neurotoxicity Research·Sonija LuziRobin M Murray
Mar 3, 2010·Annual Review of Clinical Psychology·Emma Barkus, Robin M Murray
Dec 22, 2011·International Journal of Molecular Imaging·Mathieu VerdurandKaterina Zavitsanou
Sep 6, 2012·European Addiction Research·S Fernández-ArtamendiO García-Rodríguez
Jun 2, 2010·The British Journal of Psychiatry : the Journal of Mental Science·Cécile HenquetInez Myin-Germeys
Jun 2, 2011·The British Journal of Psychiatry : the Journal of Mental Science·Maria Alice FontesAcioly L T Lacerda
Feb 11, 2010·The Journal of Nervous and Mental Disease·Elena de la SernaJosefina Castro-Fornieles
Mar 3, 2009·The Journal of Asthma : Official Journal of the Association for the Care of Asthma·Flora BacopoulouChryssa Bakoula
Jul 29, 2010·Expert Review of Neurotherapeutics·Molly K LarsonMichael T Compton
Nov 4, 2015·Brain Sciences·Balapal S Basavarajappa
Dec 3, 2014·Pharmacology & Therapeutics·Dan I LubmanMurat Yücel
Sep 10, 2013·Child and Adolescent Psychiatric Clinics of North America·Danielle Goerke, Sanjiv Kumra

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cannabis & Cognition

The effect of cannabis on cognitive functioning is being explored for short and long-term effects. Recent studies have shown conflicting results, with some showing no significant effects and others showing neuropsychological impairment. Discover the latest research on cannabis and cognition here.